7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wang Q et al. | [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis]. | 2005 | Zhong Yao Cai | pmid:16479929 |
| Guang-Da X et al. | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Endocrinol. Invest. | pmid:16483173 |
| Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
| Schoppet M et al. | TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16288714 |
| Michael H et al. | Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. | 2005 | J. Bone Miner. Res. | pmid:16294275 |
| Nicholls BM et al. | Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. | 2005 | J. Bone Miner. Res. | pmid:16294279 |
| Yeung RS | Bones, blood vessels, and the immune system: what's the link? | 2005 | J. Rheumatol. | pmid:16265680 |
| Simonini G et al. | Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. | 2005 | J. Rheumatol. | pmid:16265708 |
| Kim SM et al. | Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. | 2005 | Clin. Endocrinol. (Oxf) | pmid:16268814 |
| Zhang B et al. | [Molecular mechanism of bone absorption in osteoclast]. | 2005 | Sheng Wu Yi Xue Gong Cheng Xue Za Zhi | pmid:16422121 |
| Gaudio A et al. | Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? | 2005 | J. Endocrinol. Invest. | pmid:16277162 |
| Taubman MA et al. | Immune response: the key to bone resorption in periodontal disease. | 2005 | J. Periodontol. | pmid:16277573 |
| Bartold PM et al. | Periodontitis and rheumatoid arthritis: a review. | 2005 | J. Periodontol. | pmid:16277578 |
| Kaji H et al. | Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. | 2005 | Horm. Metab. Res. | pmid:16278780 |
| Zhou Z et al. | Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. | 2005 | Cancer | pmid:16121404 |
| Ashcroft AJ and Carding SR | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. | 2005 | Gut | pmid:16099805 |
| Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
| Daroszewska A and Ralston SH | Genetics of Paget's disease of bone. | 2005 | Clin. Sci. | pmid:16104845 |
| Rogers A and Eastell R | Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16105967 |
| Wise GE et al. | CSF-1 regulation of osteoclastogenesis for tooth eruption. | 2005 | J. Dent. Res. | pmid:16109994 |
| Huang P et al. | [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. | 2005 | Zhonghua Wai Ke Za Zhi | pmid:16083587 |
| Kwon OH et al. | The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16083856 |
| Kahl KG et al. | Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. | 2005 | Osteoporos Int | pmid:15300363 |
| Rassi CM et al. | Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. | 2005 | Cell Tissue Res. | pmid:15688188 |
| Silvestrini G et al. | Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. | 2005 | J. Mol. Histol. | pmid:15704000 |
| Zannettino AC et al. | Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. | 2005 | J. Cell. Physiol. | pmid:15799029 |
| Ferrari SL et al. | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. | 2005 | Endocrinology | pmid:15705780 |
| Tada T et al. | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. | 2005 | Int. J. Cancer | pmid:15800904 |
| Heymann D et al. | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. | 2005 | Drug Discov. Today | pmid:15708742 |
| Mandelin J et al. | Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. | 2005 | J. Rheumatol. | pmid:15801030 |
| Mezquita-Raya P et al. | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. | 2005 | Osteoporos Int | pmid:15711777 |
| Holmen SL et al. | Essential role of beta-catenin in postnatal bone acquisition. | 2005 | J. Biol. Chem. | pmid:15802266 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Bernstein CN et al. | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. | 2005 | Inflamm. Bowel Dis. | pmid:15803021 |
| Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
| Mitani M et al. | Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. | 2005 | Int. J. Mol. Med. | pmid:15806305 |
| Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
| Voskaridou E and Terpos E | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. | 2005 | Eur. J. Haematol. | pmid:15777350 |
| Mossetti G et al. | Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. | 2005 | Bone | pmid:15777635 |
| Janssens K et al. | An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. | 2005 | Bone | pmid:15777670 |
| Fábrega E et al. | Osteoprotegerin and RANKL in alcoholic liver cirrhosis. | 2005 | Liver Int. | pmid:15780054 |
| Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2005 | Nippon Rinsho | pmid:16149650 |
| Choi JY et al. | Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. | 2005 | Calcif. Tissue Int. | pmid:16151677 |
| Viereck V et al. | Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. | 2005 | J. Cell. Biochem. | pmid:16152630 |
| Yamada N et al. | Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. | 2005 | Cytokine | pmid:15996478 |
| Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
| Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
| Lau YS et al. | Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. | 2005 | Hum. Pathol. | pmid:16153456 |
| Ueland T and Bollerslev J | Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. | 2005 | Front Horm Res | pmid:16166760 |
| Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
| Frick KK et al. | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. | 2005 | Am. J. Physiol. Renal Physiol. | pmid:15972386 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
| Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Wang L et al. | Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. | 2005 | Am. J. Physiol. Endocrinol. Metab. | pmid:15585587 |
| Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
| Byrne FR et al. | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. | 2005 | Gut | pmid:15591508 |
| Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
| Zehnder AF et al. | Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. | 2005 | Laryngoscope | pmid:15630389 |
| Kees M et al. | Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. | 2005 | Thromb. Haemost. | pmid:15630493 |
| Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |
| Belibasakis GN et al. | The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. | 2005 | Infect. Immun. | pmid:15618171 |
| Liu XH et al. | Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. | 2005 | Endocrinology | pmid:15618359 |
| Cao JJ et al. | Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. | 2005 | J. Bone Miner. Res. | pmid:15619667 |
| Liu PY et al. | A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15623811 |
| Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
| Katsuyama H et al. | Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. | 2005 | Int. J. Mol. Med. | pmid:15647836 |
| Andelković Z et al. | [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. | 2005 Jul-Aug | Med. Pregl. | pmid:16296579 |
| Palma MA and Body JJ | Usefulness of bone formation markers in breast cancer. | 2005 Jul-Sep | Int. J. Biol. Markers | pmid:16240842 |
| Contractor T et al. | Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. | 2005 Mar-Apr | In Vivo | pmid:15796195 |
| Buemi M et al. | Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. | 2005 Mar-Apr | J. Nephrol. | pmid:15931642 |
| Gorczynski RM et al. | Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. | 2005 May-Jun | Acta Astronaut | pmid:15835039 |
| Pettersen I et al. | Osteoprotegerin is expressed in colon carcinoma cells. | 2005 Nov-Dec | Anticancer Res. | pmid:16309167 |
| Kraj M et al. | Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. | 2005 Sep-Oct | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:16314829 |
| Zojer N et al. | Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | 2005 Sep-Oct | Anticancer Res. | pmid:16101188 |
| Olmos JM et al. | Factors other than glucocorticoids are involved in the osteoblast activity decrease caused by tissue injury. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16487437 |
| Dobnig H et al. | Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. | 2006 | Osteoporos Int | pmid:16435076 |
| Kananen K et al. | Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? | 2006 | Osteoporos Int | pmid:16437190 |
| Lossdörfer S et al. | Maturation-state dependent response of human periodontal ligament cells to an intermittent parathyroid hormone exposure in vitro. | 2006 | J. Periodont. Res. | pmid:16409257 |
| Rosso DA et al. | Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. | 2006 | Pediatr. Res. | pmid:16439593 |
| Zangari M et al. | Response to bortezomib and activation of osteoblasts in multiple myeloma. | 2006 | Clin Lymphoma Myeloma | pmid:17026821 |
| Ostergård T et al. | Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training. | 2006 | Metab. Clin. Exp. | pmid:17046554 |
| Clancy P et al. | Assessment of a serum assay for quantification of abdominal aortic calcification. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:17053174 |
| Ricci P et al. | Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation. | 2006 | Transplantation | pmid:17164716 |
| Ivanov SD et al. | [Prognosis of efficacy of organ-saving treatment of invasive bladder cancer]. | 2006 | Vopr Onkol | pmid:17168368 |
| Secchiero P et al. | Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. | 2006 | J. Cell. Physiol. | pmid:16270354 |
| Lau YS et al. | Malignant melanoma and bone resorption. | 2006 | Br. J. Cancer | pmid:16641914 |
| Malik MH et al. | Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathway. | 2006 | Int Orthop | pmid:16583245 |
| Graziani F et al. | The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. | 2006 | Clin Oral Implants Res | pmid:16584418 |
| Fisher JL et al. | Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. | 2006 | Cancer Res. | pmid:16585187 |
| Kacena MA et al. | Megakaryocyte-mediated inhibition of osteoclast development. | 2006 | Bone | pmid:16782418 |
| Chung YH et al. | Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. | 2006 | J. Periodont. Res. | pmid:16827722 |
| Lu HK et al. | Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. | 2006 | J. Periodont. Res. | pmid:16827732 |
| Aoki K et al. | A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. | 2006 | J. Clin. Invest. | pmid:16680194 |
| Anand DV et al. | The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. | 2006 | J. Am. Coll. Cardiol. | pmid:16682312 |
| Sawajiri M et al. | Different effects of carbon ion and gamma-irradiation on expression of receptor activator of NF-kB ligand in MC3T3-E1 osteoblast cells. | 2006 | Bull. Exp. Biol. Med. | pmid:17415477 |
| Koreny T et al. | The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. | 2006 | Arthritis Rheum. | pmid:17009257 |
| Neumann E | [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?]. | 2006 | Z Rheumatol | pmid:16924451 |
| Wang L et al. | [Inhibitory effect of diacerein on osteoclastic bone destruction and its possible mechanism of action]. | 2006 | Yao Xue Xue Bao | pmid:16927832 |